Will Bupa Arabia and Tawuniya cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Encelto is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by SFDA?

The SFDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; SFDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Saudi-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Saudi Commission for Health Specialties (SCFHS) and the SFDA verifies the active license; the SFDA application records both the prescribing physician and the dispensing facility.

Can I receive Encelto at home?

The dispensing facility must be Saudi-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 290,000 to 340,000 per per eye (one-time). Delivered quote within 24h.Get my quote

Encelto access in Saudi Arabia: the SFDA named-patient pathway

How patients in the Kingdom of Saudi Arabia legally obtain Encelto (revakinagene taroretcel-lwey) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Saudi Arabia access Encelto (revakinagene taroretcel-lwey) for macular telangiectasia type 2 (MacTel) in adults through the SFDA named-patient pathway, a Saudi Food and Drug Authority-administered mechanism that allows a Saudi-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in SAR.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Encelto reaches patients in Saudi Arabia

Encelto (revakinagene taroretcel-lwey, an encapsulated cell therapy producing ciliary neurotrophic factor implanted in the eye, FDA-approved March 2025 for macular telangiectasia type 2, the first FDA-approved treatment for MacTel; marketed by Neurotech Pharmaceuticals) is not visible on the SFDA registered-drug list at sfda.gov.sa/en/drugs-list as of 2026-05-31. As an implanted cell-therapy device-drug product, Encelto's pathway in Saudi Arabia combines the SFDA Special Access Programme (institutional, Pathway B) under SFDA emergency or compassionate use regulations with the medical-device regulatory framework for the encapsulated-cell delivery vehicle. The Encelto-specific clinical justification must document: confirmed bilateral or unilateral MacTel type 2 by multimodal imaging (OCT, fundus autofluorescence, fluorescein angiography), best-corrected visual acuity baseline, ellipsoid zone defect extent, and ophthalmologic surgical-implantation team's training and capacity. Encelto is a surgically implanted intravitreal capsule device; the receiving Saudi institution must have vitreoretinal surgical capacity and post-implantation surveillance protocols. The supporting medical report must be dated within 6 months and approved by the treatment institution. SFDA processing for institutional Special Access requests is on a case-by-case basis with rapid turnaround for documented urgent need.

Where Encelto is implanted in Saudi Arabia

Encelto requires vitreoretinal surgical capacity and macular-disease specialist expertise. Saudi tertiary ophthalmology nodes equipped for the surgical implantation and post-implantation surveillance include King Khaled Eye Specialist Hospital (KKESH) in Riyadh, the country's flagship ophthalmology speciality hospital with the most extensive vitreoretinal surgery service; the King Faisal Specialist Hospital and Research Centre (KFSHRC) Department of Ophthalmology in Riyadh and Jeddah at kfshrc.edu.sa with structured macular-disease and inherited-ocular-disease services; the King Saud University Medical City Department of Ophthalmology in Riyadh; King Abdulaziz University Hospital Department of Ophthalmology in Jeddah; and Magrabi Eye Hospitals as the major private vitreoretinal centre. KKESH is the most-likely Encelto implantation node nationally; the institution publishes departmental chairs and runs a structured medical-retina service positioned for MacTel diagnostic confirmation by multimodal imaging. MacTel type 2 is a rare degenerative bilateral disease with estimated prevalence around 0.1% in the general population; the Saudi MacTel patient pool is small and concentrates at KKESH.

What Encelto costs in Saudi Arabia

The US reference price for Encelto is approximately USD 80,000 to USD 90,000 per implant per Neurotech Pharmaceuticals disclosures at launch in March 2025 (per public reporting by EvaluatePharma and AAO Retina coverage). The treatment is a single intravitreal capsule implantation per eye; bilateral cases require 2 implants. The FDA approval letter is at accessdata.fda.gov/scripts/cder/daf. No public SAR benchmark for Encelto is observed; the drug-device product is not currently SFDA-registered. Do not estimate. Price snapshot: 2026-05-31. The Saudi Riyal is USD-pegged at approximately 3.75 SAR per USD. Cost layers: cold-chain international logistics for the live-cell-therapy implant from Neurotech's US manufacturing site (mid to high four-figure USD for short-window controlled-temperature lanes), SFDA clearance fees (nominal), the implantation surgery costs at the dispensing ophthalmology hospital (general anaesthesia, vitreoretinal OR time, surgeon fee, anaesthetist fee), post-implantation surveillance imaging series, and Reserve Meds concierge fee itemised separately. The implantation procedure is a single event rather than recurring; long-term efficacy data are emerging post-FDA approval.

Funding and access barriers for Encelto in Saudi Arabia

MacTel type 2 is rare (estimated prevalence approximately 0.1%) and historically had no disease-modifying treatment; Saudi patients typically received supportive low-vision care and lifestyle modification. Encelto is the first FDA-approved disease-modifier and as a one-time implant offers a different funding profile from chronic anti-VEGF intravitreal therapies. Public-sector funding: Saudi nationals receive ophthalmology services at MOH-affiliated specialty hospitals (KKESH primarily) without direct charge; NUPCO procurement covers registered ophthalmologic drugs and devices, but Encelto is not currently on the NUPCO list. Institutional access via the SFDA Special Access Programme is the procedural route. The Council of Health Insurance Essential Benefits Package covers ophthalmology but does not currently extend to Encelto. Major Saudi cooperative health insurers (Bupa Arabia, Tawuniya, MedGulf, AXA Cooperative, Al Rajhi Takaful) typically exclude or sub-limit unregistered cell-therapy devices; corporate group policies with prior authorisation and an itemised approval letter from the prescribing ophthalmologist may include, though no precedent claim is publicly documented. Out-of-pocket self-pay supplemented by family contribution dominates the funding picture. Because MacTel is rare and Encelto recently approved, the Saudi clinical and reimbursement pathway is still maturing as of 2026-05-31.

Recent regulatory and access news for Encelto

FDA approved Encelto on 5 March 2025 for macular telangiectasia type 2 in adults based on the NTMT-03-A and NTMT-03-B phase 3 trials; this was the first FDA-approved therapy for MacTel and the second FDA-approved encapsulated cell-therapy product. The FDA approval letter is at accessdata.fda.gov/scripts/cder/daf. Neurotech Pharmaceuticals has not yet announced EMA submission or Saudi-region submission timing publicly as of 2026-05-31. The SFDA News feed at sfda.gov.sa/en/news does not document an Encelto submission. The MacTel patient community has historically been served by international MacTel registries (Lowy Medical Research Institute MacTel project) which document the natural history; case reports of post-Encelto outcomes in Saudi patients are not yet published.

Where Reserve Meds fits in Encelto cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace SFDA, and we do not replace your dispensing pharmacy. For Encelto specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Saudi Arabia, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Encelto case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the SFDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Encelto is a one-time surgical implantation performed by a vitreoretinal specialist at a certified centre; pre-operative imaging, post-operative slit-lamp surveillance, and the implant retrieval contingency are part of the protocol.

Next step

If your Saudi physician has prescribed Encelto and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Encelto case Or message us on WhatsApp